This funding marks a major milestone for the company, building on the momentum of its €7.5 million EIC Accelerator award received in 2023. The capital will be used to accelerate the clinical programs and commercialization of PamDx proprietary IOpener® platform, a ground-breaking new blood test designed for rapid measurement of protein kinases in cancer patients to optimize the use of immunotherapy.

While immunotherapy has revolutionized oncology, a significant challenge remains to identify those patients who will benefit most. PamDx’s IOpener® diagnostic blood test addresses this unmet need. From a simple blood draw, the test provides a predictive score for the likelihood of responding to immune checkpoint inhibitors (ICI) therapy. This unique technology allows clinicians to predict ICI therapy response before actual treatment begins, potentially improving outcomes for patients with metastatic cancer, including those with melanoma and non-small cell lung cancer.

“Securing this Series A funding is a powerful validation of our team’s hard work and the disruptive potential of our IOpener® technology” said John Groten, Managing Director of PamDx.

“Following the successful EIC Accelerator award, this investment provides the resources needed to execute clinical utility studies and scale the commercial activities and optimize cancer treatment for patients worldwide” said Jan van der Hoeven, Chairman of the Board of PamDx.

Wietse Mulder, Managing Partner of Myosotis Investments said: “We are pleased to support PamDx as they transition from a breakthrough innovator to a commercial-stage player in the diagnostics space”.

About IOpener® – A liquid biopsy immunotherapy guidance test
The IOpener® is a blood-based diagnostic test that supports immunotherapy guidance for melanoma and non-small cell lung cancer (NSCLC) patients. The test measures the kinase activity in peripheral blood mononuclear cells isolated from a single tube of the patient’s blood to determine the likelihood of responding to immunotherapy. The test is based on ample experience with the technology for measuring and interpreting kinase activity to support academic and clinical research. The IOpener®-NSCLC and the IOpener®-melanoma are CE-IVD registered devices that are developed and manufactured in PamDx’s ISO 13485:2016 certified facility.

About Myosotis Investments B.V.
Myosotis Investments was founded in 2024 by Dr. Wietse Mulder and is based in Zeist, The Netherlands. The firm supports organizations that have a mission-driven approach aiming to impact healthcare leading to better care of patients. The firm focuses on advancements in molecular diagnostics and life sciences. Their current portfolio includes innovative companies such as Idevax B.V., Kairos Biotech Ltd, Cyclomics B.V., Tzu Cancer Therapeutics B.V. and Scinus Cell Expansion B.V.

About PamDx
PamDx, a tradename of PamGene International B.V., has intensified its efforts to develop and commercialize a blood-based immunotherapy guidance test, the IOpener®, to improve patient outcomes. The company’s kinase-activity profiling technology and proprietary software algorithms support clinicians in their treatment decisions using the IOpener® assay. PamDx’s robust and unique peptide microarray technology for multiplex kinase-activity profiling is also used to provide dedicated assay services for patient stratification for clinical trials, biomarker discovery, and gaining mechanistic insights needed to understand human diseases. PamDx is headquartered in ‘s-Hertogenbosch, the Netherlands.

For more information:
Rinie van Beuningen, Vice President Business Development
e-mail: iopener@pamdx.com
phone: +31 (0) 73 615 80 80